AIVITA Biomedical Successfully Closes $25 Million Financing Round: Funds Support Ongoing Development of Personalized COVID-19 Prevention Vaccine
The roceeds will support clinical development of AIVITA's personalized immunotherapy programs.
The roceeds will support clinical development of AIVITA's personalized immunotherapy programs.